TrialEvaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Trial details
- Registry ID
- NCT03180684
- Phase
- Phase 2
Drug research
CELLECTRA™ 2000
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity has not yet been verified against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)NCT03180684 | Inovio Pharmaceuticals | Phase 2 | Completed | 2020-07-23Actual |
| Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy VolunteersNCT04588428 | Inovio Pharmaceuticals | Phase 2 | Completed | 2023-01-19Actual |
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
Trial details
- Registry ID
- NCT04588428
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |